Halozyme Therapeutics Inc (HALO) Balance Sheet
A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally.
Total Assets Chart for Halozyme Therapeutics Inc
Halozyme Therapeutics Inc (HALO) total assets for FY2025 were USD 2.5B, a 22.4% change from FY2024. Halozyme Therapeutics Inc's total assets grew from USD 26.1K in 2001 to USD 2.5B in 2025 (9665468.2% over 24 years). Total assets compound annual growth rate: 5-year CAGR of 34.2%, 10-year CAGR of 30.1%, 20-year CAGR of 27.2%.
Total Assets (US Dollars)
R&D as % of Revenue
Key Stats
- Market Cap
- $12.45B
- Implied Share Price
- $109.72
- Enterprise Value
- $14.68B
- Revenue (TTM)
- $1.66B
- EBITDA
- $1.05B
- Profit Margin
- 24.86%
- Trailing P/E
- 31.71
- Forward P/E
- 11.45
- Price/Book (MRQ)
- 88.91
- Price/Sales (TTM)
- 7.49
- EV/EBITDA
- 11.80
- EV/Revenue
- 8.82
- Dividend Yield
- —
- Book Value
- $1.26
- Free Cash Flow (FY2025)
- $644.59M
- Free Cash Flow Yield
- 5.18%
Snapshot as of 7th October 2026 — not point-in-time controlled, may lag the live market by a few days.